About Zyl Therapeutics
Zyl Therapeutics is a company based in Greenville (United States) founded in 2017 by Scott Pancoast. Zyl Therapeutics has raised $9.43 million across 6 funding rounds from investors including NIH, SCRA and NIH SBIR/STTR. Zyl Therapeutics offers products and services including Z-pods. Zyl Therapeutics operates in a competitive market with competitors including PanTher Therapeutics, PolyPid, Sirnaomics, Ensysce and Arcturus Therapeutics, among others.
- Headquarter Greenville, United States
- Founders Scott Pancoast
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.43 M (USD)
in 6 rounds
-
Latest Funding Round
$294 K (USD), Grant
May 31, 2023
-
Investors
NIH
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zyl Therapeutics
Zyl Therapeutics offers a comprehensive portfolio of products and services, including Z-pods.
Technology for innovative and sustained topical drug delivery.
People of Zyl Therapeutics
Unlock access to complete
Funding Insights of Zyl Therapeutics
Zyl Therapeutics has successfully raised a total of $9.43M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $294 thousand completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zyl Therapeutics
Zyl Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, SCRA and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Locked | Locked | Locked | |
|
Early-stage technology startups are funded by New York Angels network.
|
Locked | Locked | Locked |
Investor details for Zyl Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zyl Therapeutics
Investment portfolio details for Zyl Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zyl Therapeutics
Detailed financials for Zyl Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zyl Therapeutics Comparisons
Peer comparison for Zyl Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zyl Therapeutics
Zyl Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PanTher Therapeutics, PolyPid, Sirnaomics, Ensysce and Arcturus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| Locked | Locked | Locked |
Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| Locked | Locked | Locked |
Erythrocyte encapsulation systems for drug delivery are developed.
|
Detailed competitors of Zyl Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zyl Therapeutics
Complete news archive for Zyl Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zyl Therapeutics
Zyl Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Zyl Therapeutics is headquartered in Greenville, United States.
Scott Pancoast is the current CEO of Zyl Therapeutics. They have also founded this company.
Zyl Therapeutics is a funded company, having raised a total of $9.43M across 6 funding rounds to date.
Zyl Therapeutics was founded in 2017 and is based in Greenville, United States. A patented drug delivery system known as Nanopods, derived from hydrogels, is developed by the company for topical applications. Payloads including nitric oxide, curcumin, cannabis, siRNA, iron, and melanin can be delivered through this system. Operations focus on biotechnology and pharmaceutical sectors, with emphasis on nanoparticle innovations for skin-based treatments.
Zyl Therapeutics's top competitors include PanTher Therapeutics, Sirnaomics and Arcturus Therapeutics.
Zyl Therapeutics offers Z-pods.
Zyl Therapeutics has 10 investors. Key investors include NIH, SCRA, NIH SBIR/STTR, VentureSouth, and New York Angels.